Study of Pentasa® for Reducing Residual Systemic Immune Activation in Treated HIV Infection

Inclusion Criteria: * Age at least 18 * On ART for at least 1 year during which: viremia \<50 RNA copies/ml for at least 3 measurements (allowing for 1 nonconsecutive blip of \<100), and CD4 T cell count consistently \>500 during that time * CD4 T cell nadir \>350 * Last CD4 and T cell test in past 6 months Exclusion Criteria: * Plans to modify antiretroviral therapy in the next 12 weeks for any reason * History of inflammatory bowel disease or irritable bowel disease * Chronic active hepatitis B or C * History of autoimmune disease * Hypersensitivity to any component of Pentasa * Clostridium difficile infection * Receiving rectally delivered medications * Receiving anti-inflammatory medications (such as nonsteroidal anti- inflammatory drugs, steroids, or TNF inhibitors) * Receiving immunosuppressive steroids * Receiving any medications associated with bleeding risk * Hemoglobin \< 10.0 g/dL * Platelet count less than 100,000/mm3 * White blood cell count \< 2,000 cells/mm3 or \> 15,000 cells/mm3 * Symptoms of sexually transmitted infection * Antibiotics used in the last 90 days * Renal insufficiency with creatinine clearance less than 50 ml/min * Elevated transaminases greater than 2.5 times the upper limit of normal * Evidence of decompensated cirrhosis, heart failure * Pregnant or breastfeeding women